In vitro increase in chloroquine accumulation induced by dihydroethano- and ethenoanthracene derivatives in Plasmodium falciparum-parasitized erythrocytes

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 7, 2002, Pages 2061-2068

  Pradines, Bruno ^a   Alibert, Sandrine ^a   Houdoin, Carole ^a   Santelli Rouvier, Christiane ^a   Mosnier, Joel ^a   Fusai, Thierry ^a   Rogier, Christophe ^a   Barbe, Jacques ^a   Parzy, Daniel ^a  

^a SERVICE DE SANTÉ DES ARMÉES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACENE DERIVATIVE; CHLOROQUINE; DIHYDROETHANOANTHRACENE DERIVATIVE; ETHENOANTHRACENE DERIVATIVE; PROMETHAZINE; UNCLASSIFIED DRUG; VERAPAMIL; ANTIMALARIAL AGENT;

ARTICLE; CONCENTRATION RESPONSE; DRUG ACCUMULATION; DRUG POTENTIATION; DRUG STRUCTURE; IN VITRO STUDY; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; ERYTHROCYTE; METABOLISM; PARASITOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMAL; ANTHRACENES; ANTIMALARIALS; CHLOROQUINE; DRUG RESISTANCE; DRUG SYNERGISM; ERYTHROCYTES; PLASMODIUM FALCIPARUM; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; ANIMALS;

EID: 0035984775     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.7.2061-2068.2002     Document Type: Article

References (60)

1. Synergy between two calcium channel blockers, verapamil and fantofarone (SR33557), in reversing chloroquine resistance in Plasmodium falciparum
2. 9,10-(3′,4′-Pyrrolidino)-9,10-dihydroanthracene and structurally related compounds as synergistic antimalarial drugs
3. High-level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene pfcrt and the multidrug resistance gene pfmdr1
4. Selection for high level chloroquine resistance results in deamplification of pfmdr1 gene and increased sensitivity to mefloquine in Plasmodium falciparum
5. Desipramine or cyproheptadine for reversing chloroquine resistance
6. Reversal of chloroquine resistance with desipramine in isolates of Plasmodium falciparum from Central and West Africa
7. Molecular epidemiology of malaria in Yaounde, Cameroon. III. Analysis of chloroquine resistance and point mutations in the multidrug resistance 1 (pfmdr1) gene of Plasmodium falciparum
8. Molecular epidemiology of malaria in Yaounde, Cameroon. V. Analysis of the omega repetitive region of the Plasmodium falciparum CG2 gene and chloroquine resistance
9. Analysis of the key pfcrt point mutation and in vitro and in vivo response to chloroquine
10. Chloroquine potentiating action of antihistaminics in Plasmodium falciparum in vitro
11. Uptake and efflux of chloroquine by chloroquine resistant Plasmodium falciparum clones recently isolated in Africa
12. Alleles of the Plasmodicum falciparum pfmdr 1 gene appear not to be associated with chloroquine resistance in India
13. Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine
14. Relationship of global chloroquine transport and reversal of resistance in Plasmodium falciparum
15. Rapid chloroquine efflux phenotype in both chloroquine-sensitive and chloroquineresistant Plasmodium falciparum. A correlation of chloroquine sensitivity with energy-dependent drug accumulation
16. Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum
17. Reversal of chloroquine resistance of wild isolates of Plasmodium falciparum by desipramine
18. Alternative mutations at position 76 of the vacuolar transmembrane protein Pfcrt are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum
19. A P-glycoprotein homologue of Plasmodium falciparum is isolated on the digestive vacuole
20. A molecular marker for chloroquine-resistant falciparum malaria
21. An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerization by quinoline antimalarials
22. Analysis of pfcrt point mutations and chloroquine susceptibility in isolates of Plasmodium falciparum
23. Digestive vacuolar pH of intact intraerythrocytic P. falciparum either sensitive or resistant to chloroquine
24. Simulation of kinetic data on the influx and efflux of chloroquine by erythrocytes infected with P. falciparum. Evidence for a drug-importer in chloroquine sensitive strains
25. Allelic modification of cg2 and cg1 genes do not alter the chloroquine response of drug-resistant Plasmodium falciparum
26. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance
27. Amplification of the multidrug resistance gene in some chloroquine resistant isolates of P. falciparum
28. Synthesis and molecular structures of 11-benzylamido-9,10-dihydro-9,10-ethenoanthracenes
29. Fluoxetine hydrochloride enhances in vitro susceptibility to chloroquine in resistant Plasmodium falciparum
30. Quinoline-containing antimalarialsmode of action, drug resistance and its reversal. An update with unresolved puzzles
31. (Tyr) polymorphism in Lamberene
32. Potent enhancement of the sensitivity of Plasmodium falciparum to chloroquine by the bisbenzylisoquinoline alkaloid cepharanthin
33. Nucleotide binding properties of a P-glycoprotein homologue from Plasmodium falciparum
34. The crystal and molecular structures of 9,10-dihydro-9,10-ethano and ethenoanthracenes
35. Efflux of chloroquine from Plasmodium falciparum: Mechanism of chloroquine resistance
36. Reversal of Plasmodium falciparum resistance to chloroquine in Panamanian Aotus monkeys
37. Synchronization of Plasmodium falciparum erythrocytic stages in culture
38. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil
39. Verapamil reversal of chloroquine resistance in the malaria parasites Plasmodium falciparum is specific for resistant parasites and independent of weak base effect
40. In vitro and in vivo reversal of chloroquine resistance in Plasmodium falciparum with promethazine
41. Multidrug-resistance: A fascinating, clinically relevant problem in bioenergetics
42. The chemotherapy of rodent malaria. XLV. Reversal of chloroquine resistance in rodent and human Plasmodium by antihistaminic agents
43. Reversal of chloroquine resistance in falciparum malaria
44. Identification of a chloroquine importer in Plasmodium falciparum: Differences in import kinetics are genetically linked with the chloroquine resistant phenotype
45. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites
46. Complex polymorphisms in a approximately 330 kDa protein are linked to chloroquine resistant Plasmodium falciparum in Southeast Asia and Africa
47. 2+ antagonists on chloroquine resistant and chloroquine sensitive parasites
48. Role of the neurotransmitter reuptake-blocking activity of antidepressants in reversing chloroquine resistance in vitro in Plasmodium falciparum
49. Impact of chloroquine resistance on malaria mortality
50. Antimalarial drugs influence the pH dependent solubility of heme via apparent nucleation phenomena
51. The effects of chloroquine and verapamil on digestive vacuolar pH of P. falciparum either sensitive or resistant to chloroquine
52. Enhanced lysosomal acidification leads to increased chloroquine accumulation in CHO cells expressing the pfmdr1 gene
53. Reversal of chloroquine resistance in Plasmodium falciparum using combinations of chemosensitizers
54. Chloroquine uptake by P. falciparum infected human erythrocytes during in vitro cultures and its relationship to chloroquine resistance
55. Reversal of chloroquine resistance in Plasmodium falciparum by CDR 87/209 and analogues
56. Chloroquine resistance not linked to MDR-like genes in a Plasmodium falciparum cross
57. The development and spread of drug-resistant malaria
58. Amplification of pfmdr1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand
59. Susceptibility of human malaria parasites to chloroquine is pH dependent
60. Characterization of the pfmdr2 gene for P. falciparum